NASDAQ:ELVN Enliven Therapeutics Q2 2026 Earnings Report $53.16 +1.43 (+2.76%) Closing price 04:00 PM EasternExtended Trading$53.57 +0.41 (+0.78%) As of 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Enliven Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.38Beat/MissN/AOne Year Ago EPSN/AEnliven Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEnliven Therapeutics Announcement DetailsQuarterQ2 2026Date8/12/2026TimeBefore Market OpensConference Call DateMonday, August 10, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Enliven Therapeutics Earnings HeadlinesHC Wainwright Has Positive Forecast for ELVN Q2 EarningsJuly 13 at 1:12 AM | americanbankingnews.comStocks to watch: 14 names test and tease new buy zonesJuly 8, 2026 | msn.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.July 15 at 1:00 AM | Porter & Company (Ad)Enliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value LagsJuly 4, 2026 | finance.yahoo.comWhat to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%June 27, 2026 | fool.comWhat to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% RallyJune 27, 2026 | fool.comSee More Enliven Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Enliven Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enliven Therapeutics and other key companies, straight to your email. Email Address About Enliven TherapeuticsEnliven Therapeutics (NASDAQ:ELVN) is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors. The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications. Enliven applies structure-guided drug design and advanced screening technologies to optimize potency, selectivity and oral bioavailability of its lead compounds. Preclinical studies have demonstrated proof-of-concept in multiple tumor models, supporting planned clinical investigations aimed at overcoming resistance mechanisms that limit the efficacy of conventional therapies. Headquartered in the greater Boston area, Enliven Therapeutics operates in a hub of biopharmaceutical innovation and maintains strategic collaborations with academic institutions and contract research organizations. The company’s management team brings together seasoned executives and scientists with extensive experience in oncology drug discovery and clinical development. Through its focused R&D strategy, Enliven seeks to advance novel precision therapies that address critical unmet needs in cancer treatment. View Enliven Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Johnson & Johnson’s Earnings Dip Looks Like a Buying OpportunityApple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before EarningsWhy ASML’s AI Monopoly Is Still Getting StrongerAlphabet’s AI Spending Question Looms Over Q2 EarningsCPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive StocksPlot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-MergerMarriott vs. Viking: Why the Better Quarter Doesn't Mean the Better Decade Upcoming Earnings GE Aerospace (7/16/2026)Taiwan Semiconductor Manufacturing (7/16/2026)Netflix (7/16/2026)Prologis (7/16/2026)State Street (7/16/2026)U.S. Bancorp (7/16/2026)Abbott Laboratories (7/16/2026)Intuitive Surgical (7/16/2026)UnitedHealth Group (7/16/2026)Fifth Third Bancorp (7/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
